Clinical Trials Browser

Phase 2 × Hydroxyurea × Clear all

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07033598 2026-03-05

PROSPERA

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT06955169 2026-02-17

MOMENTUM-1

Phase 2 Recruiting

Meningioma

NCT06326190 2025-09-16

LUMEN-1

Phase 2 Recruiting

Meningioma

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03944915 2025-05-11

DEPEND

Phase 2 Completed

35 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03107182 2025-05-06

OPTIMA-II

Phase 2 Completed

72 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02258659 2024-09-24

OPTIMA

Phase 2 Completed

62 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT05005182 2024-09-19

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Phase 2 Terminated

3 enrolled 12 charts

Myeloproliferative Disorders, Thrombocytosis

NCT02626715 2024-07-16

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Phase 2 Completed

21 enrolled 24 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01693718 2024-01-29

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

Phase 2 Completed

Laryngeal Diseases, Neoplasms

NCT00006119 2021-02-21

Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

Phase 2 Completed

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

NCT00928707 2019-10-31

PV

Phase 2 Completed

45 enrolled 10 charts

Polycythemia Vera

NCT00468169 2019-10-09

EPIC

Phase 2 Completed

110 enrolled 14 charts

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT01964755 2019-09-23

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Phase 2 Terminated

6 enrolled 14 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Epstein-Barr Virus Infections

NCT00019474 2018-09-14

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Phase 2 Completed

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT00462735 2018-03-13

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

Phase 2 Completed

33 enrolled 15 charts

Head and Neck Neoplasms, Laryngeal Neoplasms, Nose Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

NCT00978146 2017-04-20

Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors

Phase 2 Withdrawn

Fibroma, Desmoid Tumors

NCT00706810 2017-04-13

Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

Phase 2 Completed

8 enrolled 5 charts

Brain Neoplasms, Meningioma, Neoplasms

NCT00003590 2016-05-20

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

Phase 2 Completed

29 enrolled 5 charts

Brain Neoplasms, Meningioma

NCT00004094 2014-01-06

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00002951 2013-09-05

Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer

Phase 2 Completed

GastrointestinalHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms

NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

Phase 2 Unknown

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

NCT00083187 2013-07-18

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Phase 2 Completed

MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00004089 2013-07-10

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

Phase 2 Completed

EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00003172 2013-06-21

Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT00615927 2013-03-15

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Phase 2 Completed

64 enrolled 9 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00002940 2012-10-19

Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS

Phase 2 Completed

Lymphoma

NCT00004897 2012-06-12

Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

Phase 2 Terminated

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Terminated

231 enrolled 12 charts

Glioblastoma, Glioma